Regulatory role of the transforming growth factor-β signaling pathway in the drug resistance of gastrointestinal cancers
- PMID: 34853641
- PMCID: PMC8603464
- DOI: 10.4251/wjgo.v13.i11.1648
Regulatory role of the transforming growth factor-β signaling pathway in the drug resistance of gastrointestinal cancers
Abstract
Gastrointestinal (GI) cancer, including esophageal, gastric, and colorectal cancer, is one of the most prevalent types of malignant carcinoma and the leading cause of cancer-related deaths. Despite significant advances in therapeutic strategies for GI cancers in recent decades, drug resistance with various mechanisms remains the prevailing cause of therapy failure in GI cancers. Accumulating evidence has demonstrated that the transforming growth factor (TGF)-β signaling pathway has crucial, complex roles in many cellular functions related to drug resistance. This review summarizes current knowledge regarding the role of the TGF-β signaling pathway in the resistance of GI cancers to conventional chemotherapy, targeted therapy, immunotherapy, and traditional medicine. Various processes, including epithelial-mesenchymal transition, cancer stem cell development, tumor microenvironment alteration, and microRNA biogenesis, are proposed as the main mechanisms of TGF-β-mediated drug resistance in GI cancers. Several studies have already indicated the benefit of combining antitumor drugs with agents that suppress the TGF-β signaling pathway, but this approach needs to be verified in additional clinical studies. Moreover, the identification of potential biological markers that can be used to predict the response to TGF-β signaling pathway inhibitors during anticancer treatments will have important clinical implications in the future.
Keywords: Cancer stem cells; Drug resistance; Epithelial-mesenchymal transition; Gastrointestinal cancer; MicroRNAs; Transforming growth factor-β.
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Conflict of interest statement
Conflict-of-interest statement: The authors declare that they have no conflicting interests.
Figures

Similar articles
-
The Role of the Transforming Growth Factor-β Signaling Pathway in Gastrointestinal Cancers.Biomolecules. 2023 Oct 19;13(10):1551. doi: 10.3390/biom13101551. Biomolecules. 2023. PMID: 37892233 Free PMC article. Review.
-
Duel nature of TGF-beta signaling: tumor suppressor vs. tumor promoter.Curr Opin Oncol. 2005 Jan;17(1):49-54. doi: 10.1097/01.cco.0000143682.45316.ae. Curr Opin Oncol. 2005. PMID: 15608513 Review.
-
TGF-β Signaling and Resistance to Cancer Therapy.Front Cell Dev Biol. 2021 Nov 30;9:786728. doi: 10.3389/fcell.2021.786728. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34917620 Free PMC article. Review.
-
TGF-β signaling in liver and gastrointestinal cancers.Cancer Lett. 2016 Sep 1;379(2):166-72. doi: 10.1016/j.canlet.2016.03.033. Epub 2016 Mar 30. Cancer Lett. 2016. PMID: 27039259 Free PMC article. Review.
-
Chinese medicine Bu-Fei decoction attenuates epithelial-mesenchymal transition of non-small cell lung cancer via inhibition of transforming growth factor β1 signaling pathway in vitro and in vivo.J Ethnopharmacol. 2017 May 23;204:45-57. doi: 10.1016/j.jep.2017.04.008. Epub 2017 Apr 12. J Ethnopharmacol. 2017. PMID: 28412214
Cited by
-
Comparison of efficacy and safety between endoscopic mucosal dissection and resection in the treatment of early gastrointestinal cancer and precancerous lesions: a systematic review and meta-analysis.J Gastrointest Oncol. 2023 Feb 28;14(1):165-174. doi: 10.21037/jgo-23-32. Epub 2023 Feb 24. J Gastrointest Oncol. 2023. PMID: 36915430 Free PMC article.
-
The Role of Tumor Microenvironment in Invasion and Metastasis of Esophageal Squamous Cell Carcinoma.Front Oncol. 2022 Jun 22;12:911285. doi: 10.3389/fonc.2022.911285. eCollection 2022. Front Oncol. 2022. PMID: 35814365 Free PMC article. Review.
-
Spheroids and organoids derived from colorectal cancer as tools for in vitro drug screening.Explor Target Antitumor Ther. 2024;5(2):409-431. doi: 10.37349/etat.2024.00226. Epub 2024 Apr 25. Explor Target Antitumor Ther. 2024. PMID: 38745769 Free PMC article. Review.
References
-
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. - PubMed
-
- Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70:145–164. - PubMed
-
- Piawah S, Venook AP. Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer. Cancer. 2019;125:4139–4147. - PubMed
-
- Adlard JW, Richman SD, Seymour MT, Quirke P. Prediction of the response of colorectal cancer to systemic therapy. Lancet Oncol. 2002;3:75–82. - PubMed
Publication types
LinkOut - more resources
Full Text Sources